ΒιΆΉ΄«Γ½

Jonathan Meyer, MD: Round One

In part one of a two part interview, Craig Chepke, MD, discusses how new schizophrenia drugs in development pipeline are expected to change the therapeutic landscape with Jonathan Meyer, MD.


Moderator Craig Chepke, MD, conducts a series of investigative interviews with a fellow healthcare professional, exploring each aspect of schizophrenia from a new lens. A new topic will publish each month.
December 24, 2024 β€’ 8 mins 19 secs
Up Next
Jonathan Meyer, MD: Round One
β–Ά 8 mins
image
Jonathan Meyer, MD: Round Two
β–Ά 13 mins
image
Gus Alva, MD: Round One
β–Ά 9 mins
image
Gus Alva, MD: Round Two
β–Ά 11 mins
image
A Day in the Life on an ACT Team
β–Ά 3 mins
image
Underutilization of LAIs in the U.S.
β–Ά 3 mins
image
Tips to Get a Patient to Consider LAIs
β–Ά 4 mins
image
Shared Decision Making with Patients on LAIs
β–Ά 3 mins
image
Which Formulations to Choose in LAI Treatment?
β–Ά 3 mins
image
Treatment Duration of LAIs
β–Ά 4 mins
image
Transitioning Schizophrenia Pts from Monthly to Bi-Monthly LAIs
β–Ά 2 mins
image
The Impact of Long-Acting Injectables in Managing Severe Mental Illness
β–Ά 4 mins
image
Psychedelics and Schizophrenia: Clinical Research and Evolving Perceptions
β–Ά 4 mins
image
Mechanism of Action and Neuroplasticity Impact of Psychedelics
β–Ά 5 mins
image
Psychedelics and Schizophrenia: Potential, Risks, and Historical Insights
β–Ά 5 mins
image
Which Schizophrenia Patients Might Be Candidates for Psychedelics?
β–Ά 2 mins
image
Potential Side Effects of Psychedelics in Schizophrenia Patients
β–Ά 2 mins
image